Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Mabion S.A. (MAB.WA)
PLN7.46
+0.04 (+0.54%)
PL WSE Healthcare Biotechnology
Address
ul. gen. Mariana Langiewicza 60 95-050
Konstantynów Lódzki, PL
Konstantynów Lódzki, PL
CEO
Krzysztof Kaczmarczyk
Website
mabion.eu
IPO
2010-08-10
ISIN PLMBION00016
Description
Mabion S.A. is a Polish biopharmaceutical firm dedicated to pioneering the development of biological drugs, primarily leveraging monoclonal antibody technology. The company oversees the full spectrum from research and development to the manufacturing and commercialization of therapies designed to combat a wide range of diseases, including neoplastic (cancer), autoimmune, metabolic, and neurological disorders. Key products in its portfolio include MabionCD20 and MabionHER2. Established in 2007, Mabion S.A. maintains its headquarters in Konstantynów Lódzki, Poland.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
PLN7.46
+0.04 (+0.54%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
33.0K
Beta
0.40
Float Shares
10.30M
Free Float %
63.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.06% | +0.67% | -0.13% | -9.36% | +0.81% | +2.33% | -21.80% | -58.32% | -87.81% | -89.33% | -44.66% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
7.46
Ratings Trend (MoM)
0% Bullish
| Rating | 2025-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-3.44
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-77.2% Q1'26: +68.3% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-892.3% Q1'26: +36.2% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-258.8% Q1'26: -264.6% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-334.8% Q1'26: -207.6% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-95.7% Q1'26: -65.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.0% ★ Q1'26: -0.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.29× Q1'26: -0.87× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 185.70M (-100.0%)
|
—
est: 6.50M (-100.0%)
|
—
est: 550.0K (-100.0%)
|
56.87M
est: 25.90M (+119.6%)
|
163.98M
est: 171.40M (-4.3%)
|
151.68M
est: 139.86M (+8.5%)
|
69.02M
est: 65.77M (+4.9%)
|
15.76M
est: 31.10M (-49.3%)
|
28.00M
28.00M – 28.00M
-10.0% YoY
|
52.00M
52.00M – 52.00M
+85.7% YoY
|
| EBITDA |
-55.76M
est: 63.70M (-187.5%)
|
-51.79M
est: 2.23M (-2,423.1%)
|
-44.27M
est: 188.7K (-23,568.2%)
|
118.0K
est: 8.88M (-98.7%)
|
29.63M
est: 58.79M (-49.6%)
|
58.31M
est: -7.97M (+831.6%)
|
10.20M
est: -3.75M (+372.2%)
|
-43.67M
est: -1.77M (-2,363.6%)
|
-1.60M
-1.60M – -1.60M
+10.0% YoY
|
-2.96M
-2.96M – -2.96M
-85.7% YoY
|
| EBIT |
-66.42M
est: 49.44M (-234.3%)
|
-62.90M
est: 1.73M (-3,734.9%)
|
-54.10M
est: 146.4K (-37,047.5%)
|
-8.73M
est: 6.90M (-226.6%)
|
20.65M
est: 45.63M (-54.7%)
|
51.11M
est: -18.71M (+373.2%)
|
1.50M
est: -8.80M (+117.1%)
|
-52.76M
est: -4.16M (-1,168.3%)
|
-3.75M
-3.75M – -3.75M
+10.0% YoY
|
-6.96M
-6.96M – -6.96M
-85.7% YoY
|
| Net Income |
-68.87M
est: 16.16M (-526.1%)
|
-64.71M
est: -73.70M (+12.2%)
|
-57.19M
est: -4.36M (-1,210.5%)
|
1.90M
est: -42.99M (+104.4%)
|
23.19M
est: 25.37M (-8.6%)
|
41.27M
|
-6.33M
est: -4.53M (-40.0%)
|
-62.61M
est: -22.79M (-174.8%)
|
-25.86M
-25.86M – -25.86M
-13.5% YoY
|
-11.31M
-11.31M – -11.31M
+56.3% YoY
|
| SGA |
3.22M
est: 83.10M (-96.1%)
|
3.63M
est: 2.91M (+24.7%)
|
7.95M
est: 246.1K (+3,131.6%)
|
10.99M
est: 11.59M (-5.2%)
|
28.66M
est: 76.70M (-62.6%)
|
40.18M
est: 94.85M (-57.6%)
|
41.73M
est: 44.60M (-6.4%)
|
33.93M
est: 21.09M (+60.9%)
|
18.99M
18.99M – 18.99M
-10.0% YoY
|
35.27M
35.27M – 35.27M
+85.7% YoY
|
| EPS |
-5.26
est: 1.00 (-626.0%)
|
-4.72
est: -4.56 (-3.5%)
|
-4.06
est: -0.27 (-1,403.7%)
|
0.12
est: -2.66 (+104.5%)
|
1.43
est: 1.57 (-8.9%)
|
2.55
|
-0.39
est: -0.28 (-39.3%)
|
-3.87
est: -1.41 (-174.5%)
|
-1.60
-1.60 – -1.60
-13.5% YoY
|
-0.70
-0.70 – -0.70
+56.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-25 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-68.10M
OE per share TTM
-4.20
Owner's Yield
-56.48%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
140.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR Portfolio Europe ETF SPEU | 0.00% | 730.07 | 0.07% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-2.6K
Shares Outstanding
16.16M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Krzysztof Kaczmarczyk | Chief Executive Officer & President of Management Board | 1M | male |
| Adam Pietruszkiewicz | Chief Commercial Officer, Business Development Director & Member of Management Board | 794.6K | male |
| Grzegorz Grabowicz | Chief Financial Officer & Financial Director | 781.3K | male |
| Julita Balcerek | Member of the Management Board, Operations Director & Chief Operating Officer | 560.6K | female |
| Joanna Krolasik | Head of Microbiology Division | — | female |
| Paulina Tobola | Head of Analytics Development Department | — | — |
| Pawel Pobiedzinski | Head of Logistics & Procurement | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MAB.WA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
